
FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY

July 16, 2004

**RECEIVED
CENTRAL FAX CENTER**TO: Examiner C. FRONDA
Group 1652

JUL 16 2004

FROM Lin Sun-Hoffman, PH.D.
Celera Genomics Corp.
(240) 453-3628**OFFICIAL**FAX NO: 703-872-9306# OF PAGES (incl. cover): 10

Re: U.S. Serial No. 10/014,501 filed December 14, 2001
Entitled "ISOLATED HUMAN METALLOPROTEASE PROTEINS, NUCLEIC
ACID MOLECULES ENCODING HUMAN METALLOPROTEASE
PROTEINS, AND USES THEREOF"
Atty. Docket No.: CL001177DIV2

A Terminal Disclaimer, Request for Extension of Time, RCE and Reponse in the above-
identified application follows.

PTO/SB/17 (10-03)

Approved for use through 07/31/2006, OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 1300.00)
Complete If Known

Application Number	10/014,501
Filing Date	December 14, 2001
First Named Inventor	Gennady Merkulov et al.
Examiner Name	C. FRONDA
Art Unit	1652
Attorney Docket No.	CL001177DIV2

METHOD OF PAYMENT (check all that apply)
 Check Credit card Money Order Other None
 Deposit Account:

Deposit Account Number	50-0970
Deposit Account Name	CELEA GENOMICS

The Director is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) or any underpayment of fee(s)
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code (\$)	Fee Code (\$)	Fee Code (\$)	Fee Description
1051 130	2051 65	65	Surcharge - late filing fee or oath
1052 50	2052 25	25	Surcharge - late provisional filing fee or cover sheet
1053 130	1053 130	130	Non-English specification
1812 2,520	1812 2,520	2,520	For filing a request for ex parte reexamination
1804 920*	1804 920*	920*	Requesting publication of SIR prior to Examiner action
1805 1,840*	1805 1,840*	1,840*	Requesting publication of SIR after Examiner action
1251 110	2251 55	55	Extension for reply within first month
1252 420	2252 210	210	Extension for reply within second month
1253 950	2253 475	475	Extension for reply within third month
1254 1,480	2254 740	740	Extension for reply within fourth month
1255 2,010	2255 1,005	1,005	Extension for reply within fifth month
1401 330	2401 165	165	Notice of Appeal
1402 330	2402 165	165	Filing a brief in support of an appeal
1403 290	2403 145	145	Request for oral hearing
1451 1,510	1451 1,510	1,510	Petition to institute a public use proceeding
1452 110	2452 55	55	Petition to revive - unavoidable
1453 1,330	2453 665	665	Petition to revive - unintentional
1501 1,330	2501 665	665	Utility issue fee (or reissue)
1502 480	2502 240	240	Design issue fee
1503 640	2503 320	320	Plant issue fee
1460 130	1460 130	130	Petitions to the Commissioner
1807 50	1807 50	50	Processing fee under 37 CFR 1.17(q)
1806 180	1806 180	180	Submission of Information Disclosure Stmt
8021 40	8021 40	40	Recording each patent assignment per property (times number of properties)
1809 770	2809 385	385	Filing a submission after final rejection (37 CFR 1.129(a))
1810 770	2810 385	385	For each additional invention to be examined (37 CFR 1.129(b))
1801 770	2801 385	385	Request for Continued Examination (RCE)
1802 900	1802 900	900	Request for expedited examination of a design application
SUBTOTAL (2) (\$)		110.00	
*or number previously paid, if greater. For Reissues, see above		SUBTOTAL (3) (\$ 1300.00)	

*Reduced by Basic Filing Fee Paid

(Complete if applicable)

SUBMITTED BY			
Name (Print/Type)	Lin Sun-Hoffman, PH.D.	Registration No. (Attorney/Agent)	47,983
Signature		Date	July 16, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/03 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Request
For
Continued Examination (RCE)
Transmittal**

Address to:
Commissioner for Patents
Box RCE
Washington, DC 20231

<i>Application Number</i>	10/014,501
<i>Filing Date</i>	December 14, 2001
<i>First Named Inventor</i>	Gennady MERKULOV
<i>Art Unit</i>	1652
<i>Examiner Name</i>	Christian L. Fronda
<i>Attorney Docket Number</i>	CL001177DIV2

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 CFR 1.114

a. Previously submitted

i. Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on _____
(Any unentered amendment(s) referred to above will be entered).

ii. Consider the arguments in the Appeal Brief or Rely Brief previously filed on _____

iii. Other _____

b. Enclosed

i. Amendment/Reply

iii. Information Disclosure Statement (IDS)

ii. Affidavit(s)/Declaration(s)

iv. Other _____

2. Miscellaneous

a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(l) required)

b. Other _____

3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 50-0970

i. RCE fee required under 37 CFR 1.17(e)

ii. Extension of time fee (37 CFR 1.136 and 1.17)


iii. Other Terminal Disclaimer _____

b. Check in the amount of \$ _____ enclosed

c. Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Lin Sun-Hoffman, Ph.D.	Registration No. (Attorney/Agent)	47,983
Signature			
Date	July 16, 2004		

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)	Date
Signature	

Page 1 of 2

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Box RCE, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gennady MERKULOV et al Art Unit: 1652

Serial No.10/014,501

Examiner: C. Fronda

**RECEIVED
CENTRAL FAX CENTER**

Filed: Dec. 14, 2001

Atty. Docket: CL001177DIV2

JUL 16 2004

For: ISOLATED HUMAN METALLOPROTEASE
PROTEINS, NUCLEIC ACID MOLECULES ENCODING
HUMAN METALLOPROTEASE PROTEINS,
AND USES THEREOF

OFFICIAL**Response to 1st Office Action**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed on March 3, 2004, Applicants request reconsideration of the above-referenced patent application in view of the following remarks.

In the Claims:

Claims 1-3. (canceled)

4. (previously amended) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
- (b) a nucleotide sequence comprising the nucleic acid sequence of SEQ ID No: 1;
- (c) a nucleotide sequence comprising the nucleic acid sequence of SEQ ID No: 3; and
- (d) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(c).